Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.
Saved in:
| Title: | Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies. |
|---|---|
| Authors: | Luke JJ; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania., Gelmon K; Department of Medicine, BC Cancer, University of British Columbia, Vancouver, Canada., Siu LL; Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Moreno V; START Madrid-FJD and Oncohealth Institute, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Desai J; Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Gomez-Roca CA; Department of Oncology, Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France., Carlino MS; Westmead and Blacktown Hospitals, Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia., Pachynski RK; John T. Milliken Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri., Cosman R; The Kinghorn Cancer Centre, St Vincent's Hospital Sydney, Garvan Institute of Medical Research, University of New South Wales, Sydney, New South Wales, Australia., Chu QS; Oncology Department, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada., Damian S; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Curigliano G; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.; Istituto Europeo di Oncologia, IRCCS, Milano, Italy., Tam R; Bristol Myers Squibb, Princeton, New Jersey., Wang X; Bristol Myers Squibb, Princeton, New Jersey., Jeyamohan C; Bristol Myers Squibb, Princeton, New Jersey., Wang L; Bristol Myers Squibb, Princeton, New Jersey., Zhu L; Bristol Myers Squibb, Princeton, New Jersey., Santucci-Pereira J; Bristol Myers Squibb, Princeton, New Jersey., Greenawalt DM; Bristol Myers Squibb, Princeton, New Jersey., Tabernero J; Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Jun 03; Vol. 31 (11), pp. 2134-2144. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
